Loading...
•
Dec 31, 2024
Pfizer Q4 2024 Earnings Report
Key Takeaways
Pfizer delivered strong Q4 2024 results, reporting $17.8 billion in revenue, a 21% year-over-year operational increase. Adjusted EPS was $0.63, up from $0.10 in Q4 2023. Growth was driven by increased sales in oncology, Eliquis, and the Vyndaqel family, though partially offset by a decline in Comirnaty revenue.
Revenue by Segment
Forward Guidance
Pfizer reaffirms its 2025 guidance, expecting revenue between $61-64 billion and adjusted EPS of $2.80-$3.00, with continued cost-saving measures and product growth outside COVID-related sales.
Positive Outlook
- Expected 2025 revenue in the $61-64 billion range.
- Projected adjusted EPS between $2.80 and $3.00.
- Continued cost realignment program targeting $4.5 billion in savings.
- Growth expected from non-COVID products including oncology and Eliquis.
- Manufacturing optimization program on track for cost savings.
Challenges Ahead
- Declining COVID-related revenue expected to impact total revenue.
- Some products facing generic competition leading to revenue declines.
- Supply constraints affecting oncology biosimilars.
- Declining demand for Abrysvo due to reduced vaccination rates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...